{"id":"W3110909176","doi":"10.1016/j.ahj.2020.12.002","title":"Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Boehringer Ingelheim; Bristol-Myers Squibb Canada; Pfizer UK; Johnson and Johnson; Daiichi Sankyo Company; National Institutes of Health; Bayer","keywords":"Medicine; Warfarin; Atrial fibrillation; Randomized controlled trial; Aspirin; Vitamin K antagonist; Stroke (engine); Apixaban; Clinical trial; Intensive care medicine; Internal medicine; Rivaroxaban; Cardiology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06189869,0.004092452,0.00987254,0.002285823,0.001274133,0.003036035,0.002849018,0.003301945,0.01200971],"category_scores_gemma":[0.1035396,0.001892594,0.01157654,0.003045341,0.002294629,0.003087272,0.002148144,0.004660022,0.001425698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00103494,"about_ca_system_score_gemma":0.002292054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004880155,"about_ca_topic_score_gemma":0.001110312,"domain_scores_codex":[0.9077001,0.06225916,0.01453853,0.007133185,0.006669544,0.001699517],"domain_scores_gemma":[0.9482515,0.02759082,0.01129905,0.007789986,0.003726137,0.001342505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.7496289,0.003380178,0.02837066,0.0374612,0.0962543,0.0003846822,0.0006213313,0.003605464,0.002663992,0.00846961,0.01436058,0.0547992],"study_design_scores_gemma":[0.7812436,0.0393097,0.0398754,0.002720497,0.07073309,0.0005715991,0.000198654,0.004209151,0.002760466,0.01396069,0.04404651,0.000370616],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.3138798,0.07244332,0.0818831,0.006189804,0.006445162,0.3960869,0.1031611,0.001005573,0.01890524],"genre_scores_gemma":[0.5564873,0.006941849,0.05040154,0.004690255,0.001942214,0.3490391,0.02740549,0.0001935281,0.002898748],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.06189869,"threshold_uncertainty_score":0.3273555,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.104185640088483,"score_gpt":0.342339056682663,"score_spread":0.23815341659418,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}